Inclusion Criteria:  Participants with severe hemophilia A (participant's own FVIII activity [FVIII:C] <1% Participants must be previously treated with FVIII concentrate(s) (plasma derived or recombinant) for a minimum of 50 exposure days (EDs) at the time of signing the informed consent Participant has understood the study if appropriate for his age, informed consent must be signed by the parent, the participant can only sign the assent Willingness and ability of participants and/or parents /caregivers to complete training in the use of the electronic patient diary (EPD) and to document infusions during the study  Exclusion Criteria:  History of FVIII inhibitors Current evidence of inhibitor to FVIII measured using the Nijmegen-modified Bethesda assay (>0.6 BU/mL) at the time of screening (central laboratory) Any other inherited or acquired bleeding disorder in addition to hemophilia A (e.g. von Willebrand disease, hemophilia B) Known hypersensitivity or allergic reaction to drug substance, excipients or mouse or hamster protein Any other significant medical condition that the investigator feels would be a risk to the patient or would impede the study Requires any pre-medication to tolerate FVIII treatment (e.g. antihistamines) Planned major surgery during the study Any individual who is receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months Any individual who received commercially available subcutaneous factor substitution therapy (emicizumab) within last 6 months The participant is currently participating in another investigational drug study or has participated in a clinical study involving an investigational drug within 30 days of study entry or previous participation in a clinical study with BAY94-9027